/
QNRX
$4.55+$0.10 (+2.25%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$8.9M
2M shares
52-week range
$3.25 – $41.80
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Borrow rate
115.94%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-61105.45
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | −$280.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $125.7K | $227.1K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | −$405.7K | −$227.1K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross margin | 144.9% | — | — | — | — | — | — | — |
| R&D | $8.3M | $45.6K | $244.2K | $1.6M | $2.7M | $3.3M | $3.6M | $9.8M |
| Operating income | $15.3M | −$1.6M | −$1.7M | −$6.1M | −$9.3M | −$9.4M | −$9.5M | −$16.3M |
| EBITDA | −$5.5M | −$1.5M | −$1.6M | −$20.3M | −$8.6M | −$8.6M | −$8.9M | −$15.7M |
| Net income | $15.3M | −$1.6M | −$2.1M | −$21.5M | −$9.4M | −$8.7M | −$9.0M | −$15.8M |
| Net margin | -5470.4% | — | — | — | — | — | — | — |
| EPS (diluted) | 7100.73 | -440.29 | -88.10 | -28543.20 | -22.97 | -337.47 | -66.85 | -10.63 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $13M | $-6.36 | $-8.36–$-4.35 | 2 |
| 2027 | $12M | $-2.87 | $-3.85–$-1.89 | 2 |
| 2028 | $21M | $-1.06 | $-1.19–$-0.93 | 2 |
| 2029 | $50M | $0.31 | $0.21–$0.41 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2547.49
Price
$4.55
Implied upside
+55889%
Peer comparison
Quoin Pharmaceuticals, Ltd. American Depositary Shares
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
www.quoinpharma.com- Employees
- 6
- IPO / List date
- Oct 28, 2021
- HQ
- KFAR SABA
Held by traders on TradeandTell
No one on the platform currently holds QNRX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in QNRX as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-04-09 | 1-for-35reverse |
| 2023-07-18 | 1-for-12reverse |
| 2022-08-01 | 1-for-12.5reverse |
| 2021-09-24 | 1-for-4reverse |
| 2019-10-23 | 1-for-5reverse |
Recent trades on TradeandTell
No one on the platform has traded QNRX yet.
